Abbott Laboratories Completes Acquisition of Exact Sciences
Abbott Laboratories (ABT) has officially announced the successful completion of its acquisition of Exact Sciences, a significant corporate development.
10 stories found
Abbott Laboratories (ABT) has officially announced the successful completion of its acquisition of Exact Sciences, a significant corporate development.
Abbott Laboratories (ABT) has introduced XIENCE Skypoint, a new technology aimed at advancing cardiovascular treatment options in India.
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal Bloomberg.com
Abbott Laboratories has announced a dividend of $0.63 per share, providing an update on its shareholder returns.
An article provides a preview of what to expect from Abbott Laboratories' upcoming earnings report.
An article examines if Abbott Laboratories' stock is underperforming the Nasdaq index.
Shareholders of Exact Sciences have given their approval for the company's acquisition by Abbott Laboratories.
An analysis explores whether Abbott Laboratories (ABT) presents a favorable stock investment opportunity for current buyers.
Abbott Laboratories (ABT) is anticipated to see positive performance driven by a recovery in its nutrition segment.
Abbott Laboratories has reported positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a device designed to prevent strokes.